Skip to main content
. 2021 Jul 1;12:529–550. doi: 10.2147/JBM.S317966

Table 4.

Management of Ocular Toxicity of Belamaf

Severity Extent of Vision Loss Treatment Recommendations
Grade 1 One line decline of best corrected visual acuity from baseline on Snellen Visual Acuity chart OR mild superficial keratopathy on corneal examination. Treatment to be continued at current dose without any modification
Grade 2 2 or 3 lines decline of best corrected visual acuity from baseline on visual acuity chart (not worse than 20/200) OR moderate superficial keratopathy on corneal examination. Hold belamaf until improves to grade 1 and resume same dose afterwards
Grade 3 More than 3 lines decline of best corrected visual acuity from baseline on visual acuity chart (not worse than 20/200) OR severe superficial keratopathy on corneal examination. Hold belamaf until improves to grade 1 and then resume 25% reduced dose
Grade 4 Severely reduced vision (visual acuity worse than 20/200 on Snellen Visual Acuity chart) OR corneal epithelial defects on corneal examination. Belamaf treatment termination with urgent ophthomology consult